Base de données sur les brevets canadiens / Sommaire du brevet 2585691 

Énoncé de désistement de responsabilité concernant l'information provenant de tiers

Une partie des informations de ce site Web à été fournie par des sources externes. Le gouvernement du Canada n'assume aucune responsabilité concernant la précision, l'actualité ou la fiabilité des informations fournies par les sources externes. Les utilisateurs qui désirent employer cette information devraient consulter directement la source des informations. Le contenu fournit par les sources externes n'est pas assujetti aux exigences sur les langues officielles, la protection des renseignements personnels et l'accessibilité.

Disponibilité de l'Abrégé et des Revendications

L'apparition de différences dans le texte et l'image des Revendications et de l'Abrégé dépend du moment auquel le document est publié. Les textes des Revendications et de l'Abrégé sont affichés :

  • lorsque la demande peut être examinée par le public;
  • lorsque le brevet est émis (délivrance).
(12) Brevet: (11) CA 2585691
(54) Titre français: SOLUTION OPHTALMIQUE DE BIMATOPROST AMELIOREE
(54) Titre anglais: ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
(51) Classification internationale des brevets (CIB):
  • A61K 31/5575 (2006.01)
  • A61K 9/08 (2006.01)
  • A61K 47/18 (2017.01)
  • A61P 27/06 (2006.01)
(72) Inventeurs :
  • CHANG, CHIN-MING (Etats-Unis d'Amérique)
  • CHANG, JAMES N. (Etats-Unis d'Amérique)
  • SCHIFFMAN, RHETT M. (Etats-Unis d'Amérique)
  • JORDAN, R. SCOTT (Etats-Unis d'Amérique)
  • CHANG-LIN, JOAN-EN (Etats-Unis d'Amérique)
(73) Titulaires :
  • ALLERGAN, INC. (Etats-Unis d'Amérique)
(71) Demandeurs :
  • ALLERGAN, INC. (Etats-Unis d'Amérique)
(74) Agent: GOWLING WLG (CANADA) LLP
(74) Co-agent:
(45) Délivré: 2009-05-19
(86) Date de dépôt PCT: 2006-03-14
(87) Mise à la disponibilité du public: 2006-09-28
Requête d’examen: 2007-05-10
(30) Licence disponible: S.O.
(30) Langue des documents déposés: Anglais

(30) Données de priorité de la demande:
Numéro de la demande Pays / territoire Date
11/083,261 Etats-Unis d'Amérique 2005-03-16

Abrégé français

L'invention concerne une composition comprenant entre 0,005 % et 0,02 % de bimatoprost en poids et entre 100 ppm et 250 ppm de chlorure de benzalkonium, ladite composition étant un liquide aqueux qui est préparé pour l'administration ophtalmique. L'invention concerne également une méthode qui est utile dans le traitement du glaucome ou de l'hypertension oculaire associée à ce dernier.


Abrégé anglais




A composition comprising from 0.005% to 0.02% bimatoprost by weight and from
100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an
aqueous liquid which is formulated for ophthalmic administration is disclosed
herein. A method which is useful in treating glaucoma or ocular hypertension
related thereto is also disclosed herein.


Note : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.




CLAIMS:


1. A composition comprising from 0.005% to 0.02% bimatoprost by weight and
from 0.01% to 0.025% by weight benzalkonium chloride, wherein said composition
is an
aqueous liquid which is formulated for ophthalmic administration.


2. The composition of claim 1 which further comprises EDTA.


3. The composition of claim 2 wherein the concentration of benzalkonium
chloride
is from 0.015% to 0.02%.


4. The composition of claim 3 having a pH of 7.4 which consists essentially of
0.0 15% bimatoprost, 0.02% benzalkonium chloride, from 0 to 0.03% EDTA, and
further
comprising a phosphate buffer, NaCl, and water.


5. The composition of claim 1 wherein the concentration of bimatoprost is from

0.01 % to 0.02%.


6. The composition of claim 5 wherein the concentration of bimatoprost is from

0.015% to 0.02%.


7. The composition of claim 6 wherein the concentration of benzalkonium
chloride
is from 0.015% to 0.020%.


8. The composition of claim 7 wherein the concentration of benzalkonium
chloride
is 0.02%.



11

9. The composition of claim 6 which further comprises EDTA.


10. A composition comprising 0.0 15% by weight bimatoprost, 0.02% by weight
benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, NaCl, wherein
said
composition has a pH of 7.4 and is an aqueous liquid.


11. The composition of claim 2 comprising from 0.001% to 0.15% EDTA.

12. The composition of claim 11 comprising from 0.01% to 0.1% EDTA.

13. The composition of claim 12 comprising from 0.01% to 0.05% EDTA.


14. The composition of claim 2 comprising from 0.015% to 0.025% benzalkonium
chloride.


15. A composition comprising by weight 0.0125% bimatoprost, 0.02% benzalkonium

chloride, 0.268% sodium phosphate dibasic heptahydrate, 0.014% citric acid
monohydrate, 0.81% sodium chloride, water, and wherein said composition is an
aqueous
liquid with a pH adjusted to 7.3.


16. A composition comprising by weight 0.01 % bimatoprost, 0.02% benzalkonium
chloride, 0.268% sodium phosphate dibasic heptahydrate, 0.014% citric acid
monohydrate, 0.81% sodium chloride, water, and wherein said composition is an
aqueous
liquid with a pH adjusted to 7.3.



12

17. Use of a composition comprising from 0.005% to 0.02% bimatoprost by weight

and from 0.01 % to 0.02% by weight benzalkonium chloride for treating glaucoma
or
intraocular hypertension in a mammal.


18. Use of a composition comprising from 0.005% to 0.02% bimatoprost by weight

and from 0.01% to 0.02% by weight benzalkonium chloride for the preparation of
a
medicament for treating glaucoma or intraocular hypertension in a mammal.


19. Use of a composition according to any one of claims 1 to 16 for treating
glaucoma
or intraocular hypertension in a mammal.


20. Use of a composition according to any one of claims 1 to 16 for the
preparation of
a medicament for treating glaucoma or intraocular hypertension in a mammal.


Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.


CA 02585691 2008-05-22

WO 20061101839 PCTIUS2006/009124
1

ENHANCED BIMATOPROST OPHTBALNIIC SOLUTION
By Inventors
Chin-Ming Chang, Jsmes N. Chang, Rhett M. Sch9fflnan, R Scott 3ortYan,
= and Joan-En Chan*Lin

FIELD OF THE INVENTION

This invention relates to phatmaceutieal compositions comprising
bimatoprost.

BACRGROUND OF THE IIVIDITION
DesCrintion of $dated Art
Bimatoprost, shown below, is a prostamide marketed commercially for
the treatment of glaucoma and ocular hypertension.

C
N-~
. tlFt /,

Farawla I
Benzalkonium chloride (BAK) is a preservative used in many commercial
ophthalmic products to prcvwt microbiai contamination in multi-nso psoducts.
The commercial eye drops (Lumigan; Allergan, Inc., Irvine, CA) contain
0.03% bimatoprost and 0.005% BAK. ,Although no other prostamides are
currently marketed for the treatment of glaucoma, several prostaglandin
analogs
* Trademark


CA 02585691 2007-11-28

WO 2096/101839 PCT/US2006l009124
2

are comme,rtially available which ua; BAK as a presen+ative. Thase include
latanoprost (Xalatan)*travopmst (Travatan). and unoprostone isopropyl
(Reacula), which require eigni6cantly more BAIC, from 150-200 ppm, to mcet
antimicrobial affectiveneas teats in the United States and Europe.
United States Patent No. 6,596,765 B2 discloses a compesition
comprising 0.005% or 0.0005961atanopmst and 0.2 mg/mL B?-S.
United Statea Patent No. 6,646,001 B2 disoloses compositions compiising
0.03% bimatoproat aad 0.01% BAK or "0.01% + 596 excess" BAK.

BM DESCRIPI'I0N OF THE DBA'VYIIVG FIGURFS

Figuit 1 is a plot showing tha aqueous humor concxntration of tho pareat
acid of bimatoprost (Bp) after topical administration of several formulations.
Figure 2 is a plot showing the :membrane permeability of bimatoproet (Bp) in
several different fonnlations.

DETAILED DESCRIFIJOPZOF THE DNEMQj~j

2p A composiaon ccmapadaing from 0.005% to 0.02% trimatoprost by
weight and from 100 ppm to 250 ppm benzalloaniam chlonide, wherein said
composition is an aqqeaus liquid which is fom-nlatod for ophthaimic
administration is disclosed 6erain_
A metbod which is usefiil in treating glaucoma or oarlar hypertension
related thereto is also disclosed herein.
An aqneons liqerid which is fixmulated for ophthalmic administration is
fatrnalatod such that it can be administeted topically to the eye. The comfort
should be mLximized as much as possible, although sometimes formulation
considemtions (e.g. drug stabiFity) may necessitate less then optimal comfoR.
so In certain compositions the coneentrat'son of bimatoprost is from 0.0196
to 0.02%. In other compositions the concentration of bimatoprost is from
0.015% to 0.02%.

* Trademark


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
3

In certain compositions the concentration of BAK is from 150 ppm to
200 ppm. In other compositions the concentration of BAK is from 150 ppm to
200 ppm. In other compositions the concentration of BAK is from 150 ppm to
250 ppm.
In ophthalmic compositions, a chelating agent may be used to enhance
preservative effectiveness. Suitable chelating agents are those known in the
art,
and, while not intending to be limiting, edetate salts (EDTA) are useful
chelating agents.
In certain compositions, concentration of EDTA is at least 0.001%. In
other compositions, the concentration of EDTA is at least 0.01%. In other
compositions the concentration of EDTA is 0.15% or less. In other
compositions the concentration of EDTA is 0.1% or less. In other compositions
the concentration of EDTA is 0.05% or less.
Certain compositions comprise from 150 to 250 ppm BAK and an
effective amount of EDTA.
As is known in the art, buffers are commonly used to adjust the pH to a
desirable range for ophthalmic use. Generally, a pH of around 6-S is desired,
and in certain compositions a pH of 7.4 is desired. Many buffers including
salts
of inorganic acids such as phosphate, borate, and sulfate are known.
Another commonly used excipient in ophthalmic compositions is a
viscosity-enhancing, or a thickening agent. Thickening agents are used for a
variety of reasons, ranging from improving the form of the formulation for
convenient administration to improving the contact with the eye to improve
bioavailability. The viscosity-enhancing agent may comprise a polymer
containing hydrophilic groups such as monosaccharides, polysaccharides,
ethylene oxide groups, hydroxyl groups, carboxylic acids or other charged
functional groups. While not intending to limit the scope of the invention,
some
examples of useful viscosity-enhancing agents are sodium
carboxymethylcellulose, hydroxypropylmethylcellulose, povidone, polyvinyl
alcohol, and polyethylene glycol.
In ophthalmic solutions, tonicity agents often are used to adjust the
composition of the foimulation to the desired isotonic range. Tonicity agents


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
4

are well known in the art and some examples include glycerin, mannitol,
sorbitol, sodium chloride, and other electrolytes.
One composition has a pH of 7.4 and consists essentially of 0.015%
bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a

phosphate buffer, NaCI, and water.
Another composition has a pH of 7.4 and comprises 0.02% bimatoprost,
200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer,
NaCl, and water.
Another composition has a pH of 7.4 and consists of 0.0 1% bimatoprost,
200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer,
NaCI, and water.
The best mode of making and using the present invention are described in
the following examples. These examples are given only to provide direction and
guidance in how to make and use the invention, and are not intended to limit
the
scope of the invention in any way.
One embodiment comprises 0.01% Bimatoprost, 0.02% Benzalkonium
Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate, 0.014% Citric
Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein the pH is 7.3.
Another embodiment comprises 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment comprises 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate; 0.81% Sodium Chloride, 0.03%, EDTA, and
water, wherein the pH is 7.3.
Another embodiment comprises 0.02% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists essentially of 0.01% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124

0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists essentially of 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
5 0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists essentially of 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, 0.03%, EDTA, and
water, wherein the pH is 7.3.
Another embodiment consists essentially of 0.02% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists of 0.01% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists of 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment consists of 0.015% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, 0.03%, EDTA, and
water, wherein the pH is 7.3.
Another embodiment consists of 0.02% Bimatoprost, 0.02%
Benzalkonium Chloride, 0.268% Sodium Phosphate Dibasic, Heptahydrate,
0.014% Citric Acid, Monohydrate, 0.81% Sodium Chloride, and water, wherein
the pH is 7.3.
Another embodiment comprises 0.0125% bimatoprost, 0.02%
benzalkonium chloride, 0.268% sodium phosphate dibasic heptahydrate,


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
6

0.014% citric acid monohydrate, 0.81% sodium chloride, sufficient sodium
hydride and/or hydrochloric acid to adjust the pH to 7.3, and water.
Another embodiment consists essentially of 0.0125% bimatoprost,
0.02% benzalkonium chloride, 0.268% sodium phosphate dibasic heptahydrate,
0.014% citric acid monohydrate, 0.81% sodium chloride, sufficient sodium
hydride and/or hydrochloric acid to adjust the pH to 7.3, and water.
Another embodiment consists of 0.0125% bimatoprost, 0.02%
benzalkonium chloride, 0.268% sodium phosphate dibasic heptahydrate,
0.014% citric acid monohydrate, 0.81% sodium chloride, sufficient sodium
hydride and/or hydrochloric acid to adjust the pH to 7.3, and water.
Example 1
Formulations containing 0.268% sodium phosphate dibasic heptahydrate,
0.014% citric acid, 0.83% sodium chloride, with the pH adjusted to 7.3 in qs
water, and the amounts of bimatoprost, BAK, and EDTA listed in Table 1 below
were prepared by conventional methods well known in the art.
Table 1
Formulation
1. 0.03% Bimatoprost (50 ppm BAK) Control
2. 0.03% Bimatoprost - 200 ppm BAK
3. 0.03% Bimatoprost - 0.015% TPGS (no preservative)
4. 0.03% Bimatoprost - 0.2% TPGS (no preservative)
5. 0.03% Bimatoprost - 0.4% TPGS (no preservative)
6. 0.03% Bimatoprost - 1.0% TPGS (no preservative)
Example 2
Studies were carried out to determine the effect of benzalkonium
chloride (BAK) and d-alpha tocopheryl polyethylene glycol 1000 succinate
(TPGS) on ocular absoiption of bimatoprost in vivo. For the in >>i.vo study,
eighteen female rabbits were given a single 28 L eyedrop bilaterally and
aqueous humor samples were collected (n=3 animals with 6 eyes per
foi-rnulation) at 60 min postdose. Two rabbits (4 eyes) remained untreated to
serve as pre-dose bioanalytical controls. Bimatoprost and its parent
carboxylic


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
7

acid extracted from aqueous humor and iyz vitro samples were analyzed by a
liquid chromatography tandem mass spectrometry (LC-MS/MS) method with a
quantitation range of 0.25-60 ng/mL.
Due to extensive metabolism of bimatoprost in rabbit eyes, its parent
acid was used as a surrogate for determining ocular absorption of bimatoprost.
Concentration of the acid in rabbit aqueous humor following single dose of 6
different bimatoprost fonnulations are summarized in Figure 1 and Table 2
below.
Table 2
Formulation Aqueous Humora (ng/mL)
1. 0.03% Bimatoprost (50 ppm BAK) Control 51.0 9.4
2. 0.03% Bimatoprost - 200 ppm BAK 87.2 19.0*
3. 0.03% Bimatoprost - 0.015% TPGS (no 26.1 3.3*
preservative)
4. 0.03% Bimatoprost - 0.2% TPGS (no preservative) 22.9 3.2*
5. 0.03% Bimatoprost - 0.4% TPGS (no preservative) 19.3 5.6*
6. 0.03% Bimatoprost - 1.0% TPGS (no preservative) 15.4 3.3*
a Mean SD. Per formulation, N=3 rabbits (6 eyes).
* Statistically different (p<0.05) compared to 0.03% Bimatoprost

Test formulations containing 0.015%, 0.2%, 0.4% and 1.0% TPGS resulted
in a lower aqueous humor carboxylic acid concentration compared to
Bimatoprost by 52%, 59%, 62% and 72%, respectively. In contrast, 0.03%
Bimatoprost containing 200 ppm BAK resulted in 57% higher aqueous humor
AGN 191522 concentration compared to Bimatoprost (50 ppm BAK).
While not intending to limit the scope of the invention in any way, or be
bound by theory, compared to the Bimatoprost control, formulations containing
TPGS resulted in decrease bimatoprost permeability. In contrast, formulations
with higher BAK resulted in higher permeability.

Example 3
Formulations containing 0.268% sodium phosphate dibasic heptahydrate,
0.014% citric acid, 0.83% sodium chloride, with the pH adjusted to 7.3 in qs


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
8

water, and the amounts of bimatoprost, BAK, and EDTA listed in Table 3 below
were prepared by conventional methods well known in the art.

Table 3

Formulation
A. 0.03% Bimatoprost (50 ppm BAK) - Control
B. 0.015% Bimatoprost (50 ppm BAK)
C. 0.015% Bimatoprost (50 ppm BAK) 0.03% EDTA
D. 0.015% Bimatoprost (200 ppm BAK)
E. 0.015% Bimatoprost (200 ppm BAK) 0.03% EDTA
F. 0.015% Bimatoprost (50 ppm BAK) 0.015% EDTA
G. 0.015% Bimatoprost (200 ppm BAK) 0.015% EDTA
H. 0.015%u Bimatoprost (125 ppm BAK)
1. 0.015% Bimatoprost (125 ppm BAK) 0.03% EDTA
J. 0.015% Bimatoprost (125 ppm BAK) 0.015% EDTA
K. 0.015% Bimatoprost (150 ppm BAK)
L. 0.015% Bimatoprost (150 ppm BAK) 0.1% EDTA
M. 0.015% Bimatoprost
N. 0.03% Bimatoprost
Example 4

The effect of benzalkonium chloride (BAK) and
ethylenediaminetetraacetic acid (EDTA) on bimatoprost permeability across
primary culture of rabbit corneal epithelial cell layers (RCECL). Comeal
epithelial cells were harvested from New Zealand White rabbits and cultured on
TranswellT"^ filters until confluency (Day 5). For the transport experiment,
cells
were first equilibrated in transport buffer for 1 hour at 37 C. Dosing
solution
containing 0.015% or 0.03% bimatoprost with varying concentrations of BAK
and EDTA was then applied to the apical compartment of the TranswellT"^ (2

cultures; n=3-4 per culture) and the cells were incubated at 37 C. At 30, 60,
90
and 120 minutes postdose, 200 L samples were taken from the basolateral
chamber for apical to basolateral (AB) transport. The samples were analyzed
by a liquid chromatography tandem mass spectrometry (LC-MS/MS) method
with quantitation range of 1-600 ng/mL.
The results are presented in Figure 2.


CA 02585691 2007-05-10
WO 2006/101839 PCT/US2006/009124
9

Example 5

A drop of formulation J is administered once daily topically to the eye of
a person suffering from glaucoma. After a few hours, intraocular pressure
drops
more and less hyperemia is observed than would be observed for formulation A.
Lowered intraocular pressure persists for as long as the treatment continues.

Une figure unique qui représente un dessin illustrant l’invention.

Pour une meilleure compréhension de l’état de la demande ou brevet qui figure sur cette page, la rubrique Mise en garde , et les descriptions de Brevet , États administratifs , Taxes périodiques et Historique des paiements devraient être consultées.

États admin

Titre Date
Date de délivrance prévu 2009-05-19
(86) Date de dépôt PCT 2006-03-14
(87) Date de publication PCT 2006-09-28
(85) Entrée nationale 2007-05-10
Requête d'examen 2007-05-10
(45) Délivré 2009-05-19

Historique d'abandonnement

Il n'y a pas d'historique d'abandonnement

Taxes périodiques

Description Date Montant
Dernier paiement 2020-03-06 250,00 $
Prochain paiement si taxe applicable aux petites entités 2021-03-15 225,00 $
Prochain paiement si taxe générale 2021-03-15 450,00 $

Avis : Si le paiement en totalité n’a pas été reçu au plus tard à la date indiquée, une taxe supplémentaire peut être imposée, soit une des taxes suivantes :

  • taxe de rétablissement prévue à l’article 7 de l’annexe II des Règles sur les brevets ;
  • taxe pour paiement en souffrance prévue à l’article 22.1 de l’annexe II des Règles sur les brevets ; ou
  • surtaxe pour paiement en souffrance prévue aux articles 31 et 32 de l’annexe II des Règles sur les brevets.

Les taxes sur les brevets sont ajustées au 1er janvier de chaque année. Les montants ci-dessus sont les montants actuels s'ils sont reçus au plus tard le 31 décembre de l'année en cours.
Veuillez consulter le site web des taxes de brevet de l'OPIC pour connaître les montants des taxes qui seront en vigueur à partir du 1er janvier de l'année prochaine.

Historique des paiements

Type de taxes Anniversaire Échéance Montant payé Date payée
Examen avancé 500,00 $ 2007-05-10
Requête d'examen 800,00 $ 2007-05-10
Enregistrement de documents 100,00 $ 2007-05-10
Dépôt 400,00 $ 2007-05-10
Enregistrement de documents 100,00 $ 2007-09-06
Taxe de maintien en état - Demande - nouvelle loi 2 2008-03-14 100,00 $ 2008-02-26
Expiré 2019 - Modifications après acceptation 400,00 $ 2008-09-19
Taxe Finale 300,00 $ 2009-01-20
Taxe de maintien en état - Demande - nouvelle loi 3 2009-03-16 100,00 $ 2009-02-19
Taxe de maintien en état - brevet - nouvelle loi 4 2010-03-15 100,00 $ 2010-02-18
Taxe de maintien en état - brevet - nouvelle loi 5 2011-03-14 200,00 $ 2011-02-17
Taxe de maintien en état - brevet - nouvelle loi 6 2012-03-14 200,00 $ 2012-02-17
Taxe de maintien en état - brevet - nouvelle loi 7 2013-03-14 200,00 $ 2013-02-18
Taxe de maintien en état - brevet - nouvelle loi 8 2014-03-14 200,00 $ 2014-03-10
Taxe de maintien en état - brevet - nouvelle loi 9 2015-03-16 200,00 $ 2015-03-09
Taxe de maintien en état - brevet - nouvelle loi 10 2016-03-14 250,00 $ 2016-03-07
Taxe de maintien en état - brevet - nouvelle loi 11 2017-03-14 250,00 $ 2017-03-13
Taxe de maintien en état - brevet - nouvelle loi 12 2018-03-14 250,00 $ 2018-03-12
Taxe de maintien en état - brevet - nouvelle loi 13 2019-03-14 250,00 $ 2019-03-08
Taxe de maintien en état - brevet - nouvelle loi 14 2020-03-16 250,00 $ 2020-03-06
Les titulaires actuels au dossier sont affichés en ordre alphabétique.
Titulaires actuels au dossier
ALLERGAN, INC.
Les titulaires antérieures au dossier sont affichés en ordre alphabétique.
Titulaires antérieures au dossier
CHANG, CHIN-MING
CHANG, JAMES N.
CHANG-LIN, JOAN-EN
JORDAN, R. SCOTT
SCHIFFMAN, RHETT M.
Les propriétaires antérieurs qui ne figurent pas dans la liste des « Propriétaires au dossier » apparaîtront dans d'autres documents au dossier.

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :



  • Pour visualiser une image, cliquer sur un lien dans la colonne description du document. Pour télécharger l'image (les images), cliquer l'une ou plusieurs cases à cocher dans la première colonne et ensuite cliquer sur le bouton "Télécharger sélection en format PDF (archive Zip)".
  • Liste des documents de brevet publiés et non publiés sur la BDBC.
  • Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.

Filtre Télécharger sélection en format PDF (archive Zip)
Description du
Document
Date
(yyyy-mm-dd)
Nombre de pages Taille de l’image (Ko)
Description 2008-05-22 9 354
Revendications 2008-05-22 3 67
Dessins 2008-05-22 2 20
Abrégé 2007-05-10 1 63
Revendications 2007-05-10 2 58
Dessins 2007-05-10 2 16
Description 2007-05-10 9 361
Dessins représentatifs 2007-06-06 1 7
Page couverture 2007-06-06 1 37
Revendications 2007-06-11 3 63
Dessins 2007-11-28 2 16
Revendications 2007-11-28 3 68
Description 2007-11-28 9 350
Revendications 2008-09-19 3 73
Dessins représentatifs 2009-05-05 1 8
Page couverture 2009-05-05 1 37
Poursuite-Amendment 2008-09-19 5 139
PCT 2007-05-10 4 141
Cession 2007-05-10 4 106
Correspondance 2007-05-24 1 27
Poursuite-Amendment 2007-05-24 1 11
Poursuite-Amendment 2007-06-11 2 34
Poursuite-Amendment 2007-07-06 4 161
Correspondance 2007-09-21 1 35
Correspondance 2007-10-03 1 14
Correspondance 2007-10-03 1 12
Cession 2007-09-06 4 121
Poursuite-Amendment 2007-11-28 16 546
Poursuite-Amendment 2008-02-04 2 63
Taxes 2008-02-26 1 40
Poursuite-Amendment 2008-05-22 14 373
Poursuite-Amendment 2008-10-07 1 16
Correspondance 2009-01-20 2 48